Related Experiment Video
Updated: Jul 5, 2025

Detection of Total Reactive Oxygen Species in Adherent Cells by 2',7'-Dichlorodihydrofluorescein Diacetate Staining
Published on: June 23, 2020
The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma
Akhil Shukla1, Md Gulam Musawwir Khan1, Anny Armas Cayarga1
1Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
Abstract:
SOCS1 is a tumor suppressor in hepatocellular carcinoma (HCC). Recently, we showed that a loss of SOCS1 in hepatocytes promotes NRF2 activation. Here, we investigated how SOCS1 expression in HCC cells affected oxidative stress response and modulated the cellular proteome. Murine Hepa1-6 cells expressing SOCS1 (Hepa-SOCS1) or control vector (Hepa-Vector) were treated with cisplatin or tert-butyl hydroperoxide (t-BHP). The induction of NRF2 and its target genes, oxidative stress, lipid peroxidation, cell survival and cellular proteome profiles were evaluated. NRF2 induction was significantly reduced in Hepa-SOCS1 cells. The gene and protein expression of NRF2 targets were differentially induced in Hepa-Vector cells but markedly suppressed in Hepa-SOCS1 cells. Hepa-SOCS1 cells displayed an increased induction of reactive oxygen species but reduced lipid peroxidation. Nonetheless, Hepa-SOCS1 cells treated with cisplatin or t-BHP showed reduced survival. GCLC, poorly induced in Hepa-SOCS1 cells, showed a strong positive correlation with NFE2L2 and an inverse correlation with SOCS1 in the TCGA-LIHC transcriptomic data. A proteomic analysis of Hepa-Vector and Hepa-SOCS1 cells revealed that SOCS1 differentially modulated many proteins involved in diverse molecular pathways, including mitochondrial ROS generation and ROS detoxification, through peroxiredoxin and thioredoxin systems. Our findings indicate that maintaining sensitivity to oxidative stress is an important tumor suppression mechanism of SOCS1 in HCC.
Insights
Suppressor of cytokine signaling 1 (SOCS1) maintains hepatocellular carcinoma (HCC) cell sensitivity to oxidative stress. SOCS1 suppresses NRF2 activation, impacting oxidative stress response and tumor suppression in HCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern.
- SOCS1 acts as a tumor suppressor in HCC.
- Loss of SOCS1 promotes NRF2 activation in hepatocytes.
Purpose of the Study:
- To investigate how SOCS1 expression in HCC cells influences oxidative stress response.
- To determine SOCS1's role in modulating the cellular proteome in HCC.
- To elucidate the tumor suppressive mechanisms of SOCS1 in HCC.
Main Methods:
- Utilized murine Hepa1-6 cells with and without SOCS1 expression (Hepa-SOCS1 vs. Hepa-Vector).
- Treated cells with cisplatin or tert-butyl hydroperoxide (t-BHP) to induce oxidative stress.
- Evaluated NRF2 induction, NRF2 target gene expression, oxidative stress markers, lipid peroxidation, cell survival, and proteome profiles.
Main Results:
- SOCS1 significantly reduced NRF2 induction and its target gene expression.
- Hepa-SOCS1 cells showed increased reactive oxygen species (ROS) but reduced lipid peroxidation.
- SOCS1-expressing cells exhibited reduced survival under oxidative stress conditions.
- Proteomic analysis revealed SOCS1 modulates pathways involved in ROS generation and detoxification.
Conclusions:
- SOCS1 expression suppresses NRF2 activation and modulates the cellular proteome in HCC.
- Maintaining sensitivity to oxidative stress is a key tumor suppressive function of SOCS1 in HCC.
- SOCS1 influences mitochondrial ROS generation and ROS detoxification pathways.
Related Concept Videos
Peroxisomes
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

